A Chromatography-Guided Co-Fractionation Mass Spectrometry Strategy for Rapid Profiling of Drug-Perturbed Protein Complexes

Protein complexes are central to cellular function and respond rapidly to pharmacological perturbations. Co-fractionation mass spectrometry (CoFrac-MS) is widely employed to analyze protein complexes by analyzing individual chromatographic fractions, but it is labor-intensive and slow. To address these challenges, we introduce a chromatography-guided strategy enabling rapid identification of drug-perturbed protein complexes. It combines cross-linking enhanced reversed phase liquid chromatography cofractionation (XL-CoFrac) for high-resolution separation with ChromaQuant, a custom tool for precise peak quantification and differential analysis (https://hplcfdu.shinyapps.io/ChromaQuant/). Subsequent targeted MS analyses, guided by ChromaQuant, collectively establish the XL-CoFrac-Q-MS workflow. In proof-of-concept studies, we first adopted XL-CoFrac to MCF7 cells and profiled representative protein complexes. ChromaQuant demonstrated exceptional precision, achieving coefficients of variation below 1% and replicate correlations exceeding 0.98. Furthermore, we analyzed RS4;11 leukemia cells treated with increasing concentrations of the BCL-2 inhibitor ABT-199 using the XL-CoFrac-Q-MS workflow. Seven chromatographic peaks that changed consistently with the drug concentration were selected to be identified by this approach. MS analysis of these peaks revealed cross-linked peptides from the BCL-2 associated protein complex. Specially, cross-linking peptides between BCL-2 and FKBP38 may shed light on the mechanisms underlying resistance to ABT-199. Further pathway enrichment analysis provides new insights into the molecular mechanisms driving ABT-199 induced apoptosis. Collectively, the XL-CoFrac-Q-MS strategy holds significant potential for broad applications, including rapid screening of drug targets and elucidation of protein complex dynamics across various pharmacological and pathological conditions.

Authors

Institutions

Publication Details

Journal
Analytical Chemistry
Published
2025-08-29
DOI
https://doi.org/10.1021/acs.analchem.5c02702
Primary Topic
Insect Resistance and Genetics
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

A Chromatography-Guided Co-Fractionation Mass Spectrometry Strategy for Rapid Profiling of Drug-Perturbed Protein Complexes

Xiangmin Zhang, Wei Liu, Mingxia Gao, Shun Shen et al.
Analytical Chemistry
Insect Resistance and Genetics
article

A Chromatography-Guided Co-Fractionation Mass Spectrometry Strategy for Rapid Profiling of Drug-Perturbed Protein Complexes

Xiangmin Zhang, Wei Liu, Mingxia Gao, Shun Shen, Jiayu Tang, Guoquan Yan
article en

Abstract

Protein complexes are central to cellular function and respond rapidly to pharmacological perturbations. Co-fractionation mass spectrometry (CoFrac-MS) is widely employed to analyze protein complexes by analyzing individual chromatographic fractions, but it is labor-intensive and slow. To address these challenges, we introduce a chromatography-guided strategy enabling rapid identification of drug-perturbed protein complexes. It combines cross-linking enhanced reversed phase liquid chromatography cofractionation (XL-CoFrac) for high-resolution separation with ChromaQuant, a custom tool for precise peak quantification and differential analysis (https://hplcfdu.shinyapps.io/ChromaQuant/). Subsequent targeted MS analyses, guided by ChromaQuant, collectively establish the XL-CoFrac-Q-MS workflow. In proof-of-concept studies, we first adopted XL-CoFrac to MCF7 cells and profiled representative protein complexes. ChromaQuant demonstrated exceptional precision, achieving coefficients of variation below 1% and replicate correlations exceeding 0.98. Furthermore, we analyzed RS4;11 leukemia cells treated with increasing concentrations of the BCL-2 inhibitor ABT-199 using the XL-CoFrac-Q-MS workflow. Seven chromatographic peaks that changed consistently with the drug concentration were selected to be identified by this approach. MS analysis of these peaks revealed cross-linked peptides from the BCL-2 associated protein complex. Specially, cross-linking peptides between BCL-2 and FKBP38 may shed light on the mechanisms underlying resistance to ABT-199. Further pathway enrichment analysis provides new insights into the molecular mechanisms driving ABT-199 induced apoptosis. Collectively, the XL-CoFrac-Q-MS strategy holds significant potential for broad applications, including rapid screening of drug targets and elucidation of protein complex dynamics across various pharmacological and pathological conditions.

Analytical ChemistryVol. 97(35)
Fudan University (CN), Institutes of Science and Development (CN), Pudong Medical Center (CN), Pudong New Area People's Hospital (CN)
National Natural Science Foundation of China, National Key Research and Development Program of China
Openalex Percentile: Top 80%
Insect Resistance and Genetics
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.